Supernus Pharmaceuticals Inc (SUPN)
30.83
+0.56
(+1.85%)
USD |
NASDAQ |
May 03, 16:00
30.84
+0.01
(+0.03%)
After-Hours: 20:00
Supernus Pharmaceuticals Accounts Receivable (Quarterly): 144.16M for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 144.16M |
September 30, 2023 | 141.76M |
June 30, 2023 | 136.56M |
March 31, 2023 | 143.57M |
December 31, 2022 | 165.50M |
September 30, 2022 | 164.09M |
June 30, 2022 | 158.06M |
March 31, 2022 | 145.15M |
December 31, 2021 | 148.93M |
September 30, 2021 | 133.68M |
June 30, 2021 | 137.28M |
March 31, 2021 | 127.06M |
December 31, 2020 | 140.88M |
September 30, 2020 | 133.11M |
June 30, 2020 | 126.56M |
March 31, 2020 | 119.20M |
December 31, 2019 | 87.33M |
September 30, 2019 | 86.70M |
June 30, 2019 | 84.56M |
March 31, 2019 | 79.95M |
December 31, 2018 | 102.92M |
September 30, 2018 | 77.75M |
June 30, 2018 | 74.84M |
March 31, 2018 | 67.86M |
December 31, 2017 | 65.59M |
Date | Value |
---|---|
September 30, 2017 | 56.17M |
June 30, 2017 | 51.16M |
March 31, 2017 | 38.88M |
December 31, 2016 | 41.53M |
September 30, 2016 | 36.22M |
June 30, 2016 | 34.28M |
March 31, 2016 | 30.65M |
December 31, 2015 | 25.91M |
September 30, 2015 | 23.60M |
June 30, 2015 | 17.90M |
March 31, 2015 | 19.27M |
December 31, 2014 | 17.27M |
September 30, 2014 | 15.30M |
June 30, 2014 | 10.85M |
March 31, 2014 | 9.725M |
December 31, 2013 | 5.054M |
September 30, 2013 | 7.208M |
June 30, 2013 | 0.537M |
March 31, 2013 | 1.65M |
December 31, 2012 | 0.011M |
September 30, 2012 | 0.50M |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 | 0.00 |
September 30, 2011 | 3.978M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
84.56M
Minimum
Jun 2019
165.50M
Maximum
Dec 2022
132.85M
Average
137.28M
Median
Jun 2021
Accounts Receivable (Quarterly) Benchmarks
Dynavax Technologies Corp | 40.61M |
Ligand Pharmaceuticals Inc | 32.92M |
Pacira BioSciences Inc | 105.56M |
Esperion Therapeutics Inc | 48.49M |
Collegium Pharmaceutical Inc | 179.52M |